ZNTL — Zentalis Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1725160 ·
Last close
$2.51
Market Cap
$237.63M
52W High
$6.95
52W Low
$1.21
ADV30
1,201,667
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -44,391,000 | -42,286,000 | 215,330,000 | 24,783,000 | 71,684,000 |
| Mar 2026 | 0 | — | -37,855,000 | -35,352,000 | 253,066,000 | 31,930,000 | 70,386,000 |
| Dec 2025 | 0 | — | -37,393,000 | -35,216,000 | 288,967,000 | 35,995,000 | 72,763,000 |
| Sep 2025 | 0 | — | -33,734,000 | -26,691,000 | 327,250,000 | 39,072,000 | 74,376,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-128,095,000
Investing CF
$120,808,000
Financing CF
$-5,529,000
CapEx
$-34,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.83
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,269,093,000
Inventory
—
Receivables
$0
ST Investments
$149,825,000
EBIT TTM
$-153,373,000
Pretax Income TTM
$-138,845,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -145,012,000 | -137,060,000 | 288,967,000 | 72,763,000 | 216,204,000 | -125,247,000 |
| Dec 2024 | 67,425,000 | -187,458,000 | -165,839,000 | 430,337,000 | 93,151,000 | 337,186,000 | -170,860,000 |
| Dec 2023 | 0 | -253,941,000 | -292,191,000 | 551,688,000 | 114,297,000 | 437,284,000 | -207,822,000 |
| Dec 2022 | 0 | -227,287,000 | -236,806,000 | 539,310,000 | 105,286,000 | 433,803,000 | -163,751,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-124,133,000
OpCashFlow TTM
—
Assets (Latest)
$253,066,000
Forward EPS
$-1.81
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $2.64 · call oi: 2,703 · put oi: 34
Expected Move to 2026-10-16:
±$0.50
(18.94%) —
implied range
$2.14 –
$3.14
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SIGA | SIGA TECHNOLOGIES INC | $235.67M | $3.28 | — |
| QTTB | Q32 Bio Inc. | $240.83M | $8.09 | — |
| IMRX | Immuneering Corp | $241.97M | $3.74 | — |
| EVMN | Evommune, Inc. | $232.63M | $6.41 | — |
| CAMP | Camp4 Therapeutics Corp | $232.19M | $3.70 | — |
News headlines (Yahoo Finance, 1h cache)
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
2026-10-05 11:55 · Yahoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-09-02 20:05 · Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-01 21:15 · Yahoo
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-08-17 20:01 · Yahoo
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
2026-08-13 20:01 · Yahoo
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
2026-07-20 13:26 · Yahoo
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
2026-07-17 20:15 · Yahoo
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at
2026-05-21 21:39 · Yahoo
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress
2026-05-12 20:05 · Yahoo
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 21:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.